Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Ezetimibe/Simvastatin and MK0524A in Mixed Hyperlipidemia
NCT00738985Phase 4Withdrawn
- Sponsor
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
- Start
- Nov 2009
- Primary completion
- Sep 2010
- Modality
- Small Molecules
01
Overview
Phase 4, double-blind trial of laropiprant + niacin in mixed hyperlipidemia (2 arms), sponsored by Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Primary endpoint: Lipid parameters efficacy at 18 weeks. Planned start Nov 2009; status: withdrawn.
02
Drugs
laropiprant + niacin
03
Conditions
mixed hyperlipidemia
Beyond the preview
Go deeper on NCT00738985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00738985.